Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym) - Nivothym

European Organisation for Research in Treatment of Cancer (EORTC)0 个研究点目标入组 12 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 12

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•*Relapsed/advanced thymoma B3 or thymic carcinoma not amenable to
•curative-intent radical treatment; *At least one previous line of
•platinum-based chemotherapy for advanced disease - Patients treated with
•neo-adjuvant or adjuvant platinum-based chemotherapy combined with radical
•surgery or as part of radical chemoradiotherapy are eligible if chemotherapy
•was completed less than 6 months before enrollment; *Radiological progression
•documented per RECIST 1.1 during or after completion of previous line therapy;
•*Presence of measurable disease according to RECIST 1.1.; -Disease status must
•be documented by full chest and upper abdomen (including adrenal glands) CT
•and/or MRI and brain CT and/or MRI within 28 days prior study enrollment. *At
•least 18 years; *WHO Performance Status (PS) 0-2; *Availability of FFPE tumor
•tissue (preferentially a tumor block or 10 unstained slides), notably for PD-L1
•immunohistochemistry (IHC) expression assessment. Archival material is allowed.
•Tissue must be considered adequate (assessed by a local pathologist) for
•characterization of PD-L1 status as per procedure manual; *Adequate
•hematological function: -White blood count >= 2 × 109/L; -Haemoglobin >9 g/dL;
•-Platelet count >100 × 109/L; *Adequate liver function: -Total bilirubin <1.5 ×
•ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0
•mg/dL); -LT and/or AST <2.5 × ULN (< 4 x ULN in case of liver metastasis)
•-Alkaline phosphatase <5 × ULN; *Adequate renal function: calculated creatinine
•clearance >=50 mL/min (according to Cockroft-Gault, see below); -Female CrCl =
•((140 - age in years) x weight in kg x 0.85)/ 72 x serum creatinine in mg/dL;
•-Male CrCl = ((140 - age in years) x weight in kg x 1.00)/72 x serum creatinine
•in mg/dL; *Women of child bearing potential (WOCBP) must have a negative serum
•pregnancy test within 72 hours prior to the first dose of study treatment;
•-Note: women of childbearing potential are defined as premenopausal females
•capable of becoming pregnant (i.e. females who have had any evidence of menses
•in the past 12 months, with the exception of those who had prior hysterectomy).
•However, women who have been amenorrheic for 12 or more months are still
•considered to be of childbearing potential if the amenorrhea is possibly due to
•prior chemotherapy, antiestrogens, low body weight, ovarian suppression or
•other reasons; *Patients of childbearing / reproductive potential should use
•adequate birth control measures, as defined by the investigator, during the
•study treatment period and for at least 5 months for a woman and 7 months for a
•man after the last study treatment. Note:A highly effective method of birth
•control is defined as a method which results in a low failure rate (i.e. less
•than 1% per year) when used consistently and correctly. Such methods include:
•-Combined (estrogen and progestogen containing) hormonal contraception
•associated with inhibition of ovulation (oral, intravaginal, transdermal)
•-Progestogen-only hormonal contraception associated with inhibition of
•ovulation (oral, injectable, implantable) -Intrauterine device (IUD)
•-Intrauterine hormone-releasing system (IUS) -Bilateral tubal occlusion
•-Vasectomized partner -Sexual abstinence (sexual abstinence is only acceptable
•if this is in line with the preferred and usual life

排除标准

•*Any evidence of active central nervous system (CNS) metastases and/or
•carcinomatous meningitis. Patients with previously treated brain metastases may
•participate provided they are clinically stable (i.e. without evidence of
•progression by imaging for at least four weeks prior to enrollment and any
•neurologic symptoms have returned to baseline), and have not received steroids
•(for a total equivalent dose of more than 10 mg of prednisone per day) for at
•least 7 days prior to enrollment; *Prior treatment with anti-PD-1,
•anti-PD-L1/2, anti-CD137, CTLA-4 modulators; *Presence of acetylcholine
•receptor antibodies; *Current participation in any other clinical research or
•treatment with an investigational agent or use of an investigational device
•within 4 weeks of enrollment; *Known active Hepatitis B (e.g., positive HBsAg
•result) or C (e.g., HCV RNA[qualitative] is detected) or known history or
•current evidence of Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies);
•*If CT has to be used, known contra-indications for CT with IV contrast;
•*Chronic use of immunosuppressive agents and/or systemic corticosteroids or any
•use in the last 15 days prior to enrollment; -Corticosteroid use as
•premedication for IV contrast allergies/reactions is allowed; -Daily prednisone
•at doses up to 10 mg or equivalent doses of any other corticosteroid is allowed
•for example as replacement therapy; *History of interstitial lung disease (ILD)
•OR pneumonitis (other than COPD exacerbation) that has required oral or IV
•steroids; *Active autoimmune disease that has required systemic treatment in
•the past 2 years (i.e. with use of disease modifying agents, corticosteroids or
•immunosuppressive drugs). Replacement therapy (i.e., thyroxine, insulin, or
•physiologic corticosteroid replacement therapy for adrenal or pituitary
•insufficiency, etc.) is not considered a form of systemic treatment and is
•allowed; *Live vaccines within 30 days prior to the first dose of study therapy
•and while participating in study. Examples of live vaccines include, but are
•not limited to, the following: measles, mumps, rubella, chicken pox, yellow
•fever, H1N1 flu, rabies, BCG, and typhoid vaccine. *Autoimmune paraneoplastic
•syndrome requiring immunosuppressive or dedicated treatment. Particular
•attention should be given to detecting any minor myasthenia signs or positive
•autoantibodies at enrollment; *History of any other hematologic or primary
•solid tumor malignancy, unless in remission for at least 5 years. pT1-2
•prostatic cancer Gleason score < 6, superficial bladder cancer, non
•melanomatous skin cancer or carcinoma in situ of the cervix are allowed;
•*Previous allogeneic tissue/solid organ transplant; *Active infection requiring
•therapy; *Surgery or chemotherapy related toxicity that have not resolved to a
•grade 1, with the exception of alopecia, fatigue, neuropathy and lack of
•appetite /nausea; *Severe comorbidities that in the opinion of the investigator
•might hamper participation to the study and/or treatment administration; *Any
•psychological, familial, sociological or geographical condition potentially
•hampering compliance with the study protocol and follow-up schedule; those
•conditions should be discussed with the patient before registration in the

研究者

发起方

European Organisation for Research in Treatment of Cancer (EORTC)

相似试验

进行中（未招募）

1 期

Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapy

EUCTR2015-005504-28-NLEuropean Organisation for Research and Treatment of Cancer80

进行中（未招募）

1 期

Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapy

EUCTR2015-005504-28-GBEuropean Organisation for Research and Treatment of Cancer80

招募中

2 期

Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)

2023-508658-24-00European Organisation For Research And Treatment Of Cancer99

进行中（未招募）

1 期

Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapytype B3 thymoma and thymic carcinomaMedDRA version: 20.0 Level: PT Classification code 10061031 Term: Thymoma malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-005504-28-ESEuropean Organisation for Research and Treatment of Cancer80

进行中（未招募）

不适用

A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer - NAFemale patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.

EUCTR2004-000838-36-HUPharmexa A/S60